Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of $11.88 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $4.06 per share was 5.4% below analysts’ consensus estimates.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
